Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

AZIZ ISMAIL SHAIBANI

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1164423588
CMS profile
1108296
Location
HOUSTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$150.53

3 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $150.53 3

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
CSL Behring $121.73 1
Alexion Pharmaceuticals, Inc. $28.80 2

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

AZIZ ISMAIL SHAIBANI

NPI 1164423588 · CMS profile ID 1108296

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

HOUSTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1164423588?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
AZIZ ISMAIL SHAIBANI, NPI 1164423588, CMS profile ID 1108296. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1164423588?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). AZIZ ISMAIL SHAIBANI, NPI 1164423588, CMS profile ID 1108296. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1164423588?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
AZIZ ISMAIL SHAIBANI, NPI 1164423588, CMS profile ID 1108296, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1164423588?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

3 matching records · $150.53 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 3 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–3 of 3.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
CSL Behring $121.7305/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 683858909 CMS
Alexion Pharmaceuticals, Inc. $10.8003/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695585833 CMS
Alexion Pharmaceuticals, Inc. $18.0002/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695585809 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $150.53 3
PY2022 $156.84 2
PY2023 $17.75 1
PY2025 $146.30 6

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2022, 2023, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2022 , PY2023 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,532,027.97 451
PY2024 Principal investigator $1,574,518.05 897
PY2023 Principal investigator $948,026.50 160
PY2022 Principal investigator $516,060.09 29
PY2021 Principal investigator $553,923.14 58
PY2020 Principal investigator $220,943.95 29
PY2019 Principal investigator $182,148.36 15

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

451 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $680.00 12/31/2025 Non-covered Recipient Entity
Houston Neurocare PA
A PHASE 3 MULTICENTER DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06823859 IN PARTICIPANTS WITH ACTIVE IDIOPATHIC INFLAMMATORY MYOPATHIES INCLUDING PARTICIPANTS WITH ACTIVE DERMATOMYOSITIS OR POLYMYOSITIS No dispute reported 06/30/2026 1228724166
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,203.41 12/26/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184280338
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,758.80 12/26/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184280340
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,088.66 12/26/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184280342
Principal investigator 1 PFIZER INC. $8,538.60 12/25/2025 Non-covered Recipient Entity
Houston Neurocare PA
A PHASE 3 MULTICENTER DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06823859 IN PARTICIPANTS WITH ACTIVE IDIOPATHIC INFLAMMATORY MYOPATHIES INCLUDING PARTICIPANTS WITH ACTIVE DERMATOMYOSITIS OR POLYMYOSITIS No dispute reported 06/30/2026 1228734557
Principal investigator 1 ARGENX US, INC. $1,365.00 12/19/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237150960
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $1,120.00 12/19/2025 Non-covered Recipient Entity
Houston Neurocare PA
hase Ib Open Label Basket Trial of RAY121 to Inhibit Classical Complement Pathway in Immunological Diseases (RAINBOW Trial) No dispute reported 06/30/2026 1211613539
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $856.65 12/19/2025 Non-covered Recipient Entity
Houston Neurocare PA
hase Ib Open Label Basket Trial of RAY121 to Inhibit Classical Complement Pathway in Immunological Diseases (RAINBOW Trial) No dispute reported 06/30/2026 1211613552
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $4,572.00 12/10/2025 Non-covered Recipient Entity
Houston Neurocare PA
hase Ib Open Label Basket Trial of RAY121 to Inhibit Classical Complement Pathway in Immunological Diseases (RAINBOW Trial) No dispute reported 06/30/2026 1211613508
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $3,497.00 12/10/2025 Non-covered Recipient Entity
Houston Neurocare PA
hase Ib Open Label Basket Trial of RAY121 to Inhibit Classical Complement Pathway in Immunological Diseases (RAINBOW Trial) No dispute reported 06/30/2026 1211613513
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $193.00 12/10/2025 Non-covered Recipient Entity
Houston Neurocare PA
hase Ib Open Label Basket Trial of RAY121 to Inhibit Classical Complement Pathway in Immunological Diseases (RAINBOW Trial) No dispute reported 06/30/2026 1211613535
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $921.00 12/10/2025 Non-covered Recipient Entity
Houston Neurocare PA
hase Ib Open Label Basket Trial of RAY121 to Inhibit Classical Complement Pathway in Immunological Diseases (RAINBOW Trial) No dispute reported 06/30/2026 1211613547
Principal investigator 1 ARGENX US, INC. $585.00 12/04/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237150909
Principal investigator 1 ARGENX US, INC. $2,145.00 12/04/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
A Phase 3, Single-Arm, Multicenter, Open-label Extension of Study ARGX-113-2007 to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237150945
Principal investigator 1 ARGENX US, INC. $1,755.00 12/04/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
A Phase 3, Single-Arm, Multicenter, Open-label Extension of Study ARGX-113-2007 to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237150949
Principal investigator 1 ARGENX US, INC. $2,856.85 12/04/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237150952
Principal investigator 1 ARGENX US, INC. $3,382.00 12/04/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
A Phase 3, Single-Arm, Multicenter, Open-label Extension of Study ARGX-113-2007 to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237150964
Principal investigator 1 ARGENX US, INC. $70.00 12/01/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237151125
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $2,793.00 12/01/2025 Non-covered Recipient Entity
Houston Neurocare PA
hase Ib Open Label Basket Trial of RAY121 to Inhibit Classical Complement Pathway in Immunological Diseases (RAINBOW Trial) No dispute reported 06/30/2026 1211613505
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $1,061.00 12/01/2025 Non-covered Recipient Entity
Houston Neurocare PA
hase Ib Open Label Basket Trial of RAY121 to Inhibit Classical Complement Pathway in Immunological Diseases (RAINBOW Trial) No dispute reported 06/30/2026 1211613518
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $4,572.00 12/01/2025 Non-covered Recipient Entity
Houston Neurocare PA
hase Ib Open Label Basket Trial of RAY121 to Inhibit Classical Complement Pathway in Immunological Diseases (RAINBOW Trial) No dispute reported 06/30/2026 1211613522
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $4,572.00 12/01/2025 Non-covered Recipient Entity
Houston Neurocare PA
hase Ib Open Label Basket Trial of RAY121 to Inhibit Classical Complement Pathway in Immunological Diseases (RAINBOW Trial) No dispute reported 06/30/2026 1211613526
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $193.00 12/01/2025 Non-covered Recipient Entity
Houston Neurocare PA
hase Ib Open Label Basket Trial of RAY121 to Inhibit Classical Complement Pathway in Immunological Diseases (RAINBOW Trial) No dispute reported 06/30/2026 1211613530
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $921.00 12/01/2025 Non-covered Recipient Entity
Houston Neurocare PA
hase Ib Open Label Basket Trial of RAY121 to Inhibit Classical Complement Pathway in Immunological Diseases (RAINBOW Trial) No dispute reported 06/30/2026 1211613543
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,002.60 11/28/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184266479
Principal investigator 1 PFIZER INC. $3,091.20 11/26/2025 Non-covered Recipient Entity
Houston Neurocare PA
A PHASE 3 MULTICENTER DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06823859 IN PARTICIPANTS WITH ACTIVE IDIOPATHIC INFLAMMATORY MYOPATHIES INCLUDING PARTICIPANTS WITH ACTIVE DERMATOMYOSITIS OR POLYMYOSITIS No dispute reported 06/30/2026 1228729658
Principal investigator 1 ARGENX US, INC. $1,755.00 11/25/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237150937
Principal investigator 1 ARGENX US, INC. $2,757.40 11/25/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237150941
Principal investigator 1 ARGENX US, INC. $2,275.00 11/25/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237150972
Principal investigator 1 ARGENX US, INC. $2,315.40 11/20/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
A Phase 3, Single-Arm, Multicenter, Open-label Extension of Study ARGX-113-2007 to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237150933
Principal investigator 1 ARGENX US, INC. $7,222.45 11/07/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
A Phase 3, Single-Arm, Multicenter, Open-label Extension of Study ARGX-113-2007 to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237150929
Principal investigator 1 ARGENX US, INC. $5,326.95 11/07/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237150968
Principal investigator 1 ARGENX US, INC. $1,170.00 11/07/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
A Phase 3, Single-Arm, Multicenter, Open-label Extension of Study ARGX-113-2007 to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237150987
Principal investigator 1 Novartis Pharmaceuticals Corporation $326,181.07 11/07/2025 Non-covered Recipient Entity
NERVE AND MUSCLE CENTER OF TEXAS
A randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy, safety, and tolerability of iptacopan in patients with generalized Myasthenia Gravis (gMG), followed by an open label extension phase No dispute reported 06/30/2026 1190302535
Principal investigator 1 PFIZER INC. $2,937.20 11/04/2025 Non-covered Recipient Entity
Houston Neurocare PA
A PHASE 3 MULTICENTER DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06823859 IN PARTICIPANTS WITH ACTIVE IDIOPATHIC INFLAMMATORY MYOPATHIES INCLUDING PARTICIPANTS WITH ACTIVE DERMATOMYOSITIS OR POLYMYOSITIS No dispute reported 06/30/2026 1228727527
Principal investigator 1 ARGENX US, INC. $70.00 11/01/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237151133
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,120.26 10/30/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184255791
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,987.78 10/30/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184255793
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,002.60 10/30/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184255795
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,235.02 10/30/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184255797
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,088.66 10/30/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184255799
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,758.80 10/30/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184255801
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,644.05 10/30/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184255803
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,120.26 10/30/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184255805
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,235.02 10/30/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184255807
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,644.05 10/30/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184255809
Principal investigator 1 ARGENX US, INC. $1,170.00 10/29/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
A Phase 3, Single-Arm, Multicenter, Open-label Extension of Study ARGX-113-2007 to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237150976
Principal investigator 1 PFIZER INC. $1,358.00 10/28/2025 Non-covered Recipient Entity
Houston Neurocare PA
A PHASE 3 MULTICENTER DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06823859 IN PARTICIPANTS WITH ACTIVE IDIOPATHIC INFLAMMATORY MYOPATHIES INCLUDING PARTICIPANTS WITH ACTIVE DERMATOMYOSITIS OR POLYMYOSITIS No dispute reported 06/30/2026 1228741959
Principal investigator 1 ARGENX US, INC. $1,745.90 10/23/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
A Phase 3, Single-Arm, Multicenter, Open-label Extension of Study ARGX-113-2007 to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237150921
Principal investigator 1 ARGENX US, INC. $2,702.15 10/23/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237150925
Principal investigator 1 ARGENX US, INC. $3,491.80 10/16/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
A Phase 3, Single-Arm, Multicenter, Open-label Extension of Study ARGX-113-2007 to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237150905
Principal investigator 1 ARGENX US, INC. $975.00 10/16/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237150917
Principal investigator 1 ARGENX US, INC. $585.00 10/16/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
A Phase 3, Single-Arm, Multicenter, Open-label Extension of Study ARGX-113-2007 to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237150956
Principal investigator 1 ARGENX US, INC. $5,404.30 10/16/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237150983
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $67.50 10/15/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184250147
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 10/15/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184250149
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $202.50 10/15/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184250151
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $202.50 10/15/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184250153
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $67.50 10/15/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184250155
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $500.00 10/15/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184250157
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $67.50 10/15/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184250159
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 10/15/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184250161
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $500.00 10/15/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184250163
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $67.50 10/15/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184250165
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $500.00 10/15/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184250167
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $67.50 10/15/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184250169
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 10/15/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184250171
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 10/15/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184250173
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 10/15/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184250175
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 10/15/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184250177
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $67.50 10/15/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184250179
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 10/15/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184250181
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $67.50 10/15/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184250183
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $67.50 10/15/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184250185
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $67.50 10/15/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184250187
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 10/15/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184250189
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 10/15/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184250191
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $500.00 10/15/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184250193
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 10/15/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184250195
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 10/15/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184250197
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 10/15/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184250199
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $67.50 10/15/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184250201
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $67.50 10/15/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184250203
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 10/15/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184250205
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $67.50 10/15/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184250207
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $67.50 10/15/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184250209
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 10/15/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184250211
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $202.50 10/15/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184250213
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 10/15/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184250215
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $202.50 10/15/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184250217
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 10/15/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184250219
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 10/15/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184250221
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $67.50 10/15/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184250223
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 10/15/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184250225
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 10/15/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184250227
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 10/15/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184250229
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $67.50 10/15/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184250231
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $67.50 10/15/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184250233
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $67.50 10/15/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184250235
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $67.50 10/15/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184250237
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $1,166.00 10/10/2025 Non-covered Recipient Entity
Houston Neurocare PA
hase Ib Open Label Basket Trial of RAY121 to Inhibit Classical Complement Pathway in Immunological Diseases (RAINBOW Trial) No dispute reported 06/30/2026 1211613465
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $5,383.00 10/10/2025 Non-covered Recipient Entity
Houston Neurocare PA
hase Ib Open Label Basket Trial of RAY121 to Inhibit Classical Complement Pathway in Immunological Diseases (RAINBOW Trial) No dispute reported 06/30/2026 1211613470
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $193.00 10/10/2025 Non-covered Recipient Entity
Houston Neurocare PA
hase Ib Open Label Basket Trial of RAY121 to Inhibit Classical Complement Pathway in Immunological Diseases (RAINBOW Trial) No dispute reported 06/30/2026 1211613474
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $193.00 10/10/2025 Non-covered Recipient Entity
Houston Neurocare PA
hase Ib Open Label Basket Trial of RAY121 to Inhibit Classical Complement Pathway in Immunological Diseases (RAINBOW Trial) No dispute reported 06/30/2026 1211613478
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $3,279.00 10/10/2025 Non-covered Recipient Entity
Houston Neurocare PA
hase Ib Open Label Basket Trial of RAY121 to Inhibit Classical Complement Pathway in Immunological Diseases (RAINBOW Trial) No dispute reported 06/30/2026 1211613483
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $210.50 10/10/2025 Non-covered Recipient Entity
Houston Neurocare PA
hase Ib Open Label Basket Trial of RAY121 to Inhibit Classical Complement Pathway in Immunological Diseases (RAINBOW Trial) No dispute reported 06/30/2026 1211613488
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $283.10 10/10/2025 Non-covered Recipient Entity
Houston Neurocare PA
hase Ib Open Label Basket Trial of RAY121 to Inhibit Classical Complement Pathway in Immunological Diseases (RAINBOW Trial) No dispute reported 06/30/2026 1211613491
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $3,454.00 10/10/2025 Non-covered Recipient Entity
Houston Neurocare PA
hase Ib Open Label Basket Trial of RAY121 to Inhibit Classical Complement Pathway in Immunological Diseases (RAINBOW Trial) No dispute reported 06/30/2026 1211613496
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $4,397.00 10/10/2025 Non-covered Recipient Entity
Houston Neurocare PA
hase Ib Open Label Basket Trial of RAY121 to Inhibit Classical Complement Pathway in Immunological Diseases (RAINBOW Trial) No dispute reported 06/30/2026 1211613499
Principal investigator 1 ARGENX US, INC. $2,591.65 10/09/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
A Phase 3, Single-Arm, Multicenter, Open-label Extension of Study ARGX-113-2007 to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237150897
Principal investigator 1 ARGENX US, INC. $2,569.55 10/09/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237150901
Principal investigator 1 PFIZER INC. $8,488.20 10/08/2025 Non-covered Recipient Entity
Houston Neurocare PA
A PHASE 3 MULTICENTER DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06823859 IN PARTICIPANTS WITH ACTIVE IDIOPATHIC INFLAMMATORY MYOPATHIES INCLUDING PARTICIPANTS WITH ACTIVE DERMATOMYOSITIS OR POLYMYOSITIS No dispute reported 06/30/2026 1228740286
Principal investigator 1 ARGENX US, INC. $2,856.85 10/03/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237150913
Principal investigator 1 ARGENX US, INC. $1,365.00 10/03/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237150979
Principal investigator 1 ARGENX US, INC. $70.00 10/01/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237151129
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $3,101.90 09/24/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
LX9211.1-204-DPN No dispute reported 06/30/2026 1248067671
Principal investigator 1 ARGENX US, INC. $2,757.40 09/23/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237151085
Principal investigator 1 ARGENX US, INC. $585.00 09/18/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
A Phase 3, Single-Arm, Multicenter, Open-label Extension of Study ARGX-113-2007 to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237151012
Principal investigator 1 ARGENX US, INC. $5,514.80 09/18/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237151065
Principal investigator 1 ARGENX US, INC. $1,170.00 09/18/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
A Phase 3, Single-Arm, Multicenter, Open-label Extension of Study ARGX-113-2007 to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237151077
Principal investigator 1 ARGENX US, INC. $2,856.85 09/12/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237151054
Principal investigator 1 ARGENX US, INC. $2,665.00 09/12/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237151074
Principal investigator 1 ARGENX US, INC. $852.00 09/04/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
A Phase 3, Single-Arm, Multicenter, Open-label Extension of Study ARGX-113-2007 to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237150996
Principal investigator 1 ARGENX US, INC. $5,409.40 09/04/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237151008
Principal investigator 1 ARGENX US, INC. $1,365.00 09/04/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
A Phase 3, Single-Arm, Multicenter, Open-label Extension of Study ARGX-113-2007 to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237151028
Principal investigator 1 GlaxoSmithKline, LLC. $195.48 09/04/2025 Non-covered Recipient Entity
NERVE AND MUSCLE CENTER OF TEXAS
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192144261
Principal investigator 1 GlaxoSmithKline, LLC. $33,720.72 09/04/2025 Non-covered Recipient Entity
NERVE AND MUSCLE CENTER OF TEXAS
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192182003
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $2,500.00 09/03/2025 Non-covered Recipient Entity
Houston Neurocare PA
hase Ib Open Label Basket Trial of RAY121 to Inhibit Classical Complement Pathway in Immunological Diseases (RAINBOW Trial) No dispute reported 06/30/2026 1211613454
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $273.60 09/03/2025 Non-covered Recipient Entity
Houston Neurocare PA
hase Ib Open Label Basket Trial of RAY121 to Inhibit Classical Complement Pathway in Immunological Diseases (RAINBOW Trial) No dispute reported 06/30/2026 1211613457
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $10,000.00 09/03/2025 Non-covered Recipient Entity
Houston Neurocare PA
hase Ib Open Label Basket Trial of RAY121 to Inhibit Classical Complement Pathway in Immunological Diseases (RAINBOW Trial) No dispute reported 06/30/2026 1211613460
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $280.00 09/03/2025 Non-covered Recipient Entity
Houston Neurocare PA
hase Ib Open Label Basket Trial of RAY121 to Inhibit Classical Complement Pathway in Immunological Diseases (RAINBOW Trial) No dispute reported 06/30/2026 1211613463
Principal investigator 1 ARGENX US, INC. $70.00 09/01/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237151144
Principal investigator 1 ARGENX US, INC. $5,139.10 08/26/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237151046
Principal investigator 1 ARGENX US, INC. $1,170.00 08/21/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237151036
Principal investigator 1 ARGENX US, INC. $2,839.85 08/14/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237151032
Principal investigator 1 ARGENX US, INC. $1,901.45 08/07/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
A Phase 3, Single-Arm, Multicenter, Open-label Extension of Study ARGX-113-2007 to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237151016
Principal investigator 1 ARGENX US, INC. $2,569.55 08/07/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237151020
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,521.50 08/06/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184224514
Principal investigator 1 PFIZER INC. $3,511.20 08/02/2025 Non-covered Recipient Entity
Houston Neurocare PA
A PHASE 3 MULTICENTER DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06823859 IN PARTICIPANTS WITH ACTIVE IDIOPATHIC INFLAMMATORY MYOPATHIES INCLUDING PARTICIPANTS WITH ACTIVE DERMATOMYOSITIS OR POLYMYOSITIS No dispute reported 06/30/2026 1228765653
Principal investigator 1 ARGENX US, INC. $70.00 08/01/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237151140
Principal investigator 1 ARGENX US, INC. $5,713.70 07/31/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237151024
Principal investigator 1 Amgen Inc. $374.85 07/28/2025 Non-covered Recipient Entity
NERVE AND MUSCLE CENTER OF TX
P3 Inebilizumab in Adults w/MG (MINT) No dispute reported 06/30/2026 1246645024
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,203.41 07/28/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184220566
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,002.60 07/28/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184220568
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,203.41 07/28/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184220570
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,758.80 07/28/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184220572
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,987.78 07/28/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184220574
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,235.02 07/28/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184220576
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,644.05 07/28/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184220578
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,644.05 07/28/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184220580
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,002.60 07/28/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184220582
Principal investigator 1 Alexion Pharmaceuticals, Inc. $46,657.20 07/25/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
A Phase 3, Randomized, Double blind, Placebo controlled, Parallel, Multicenter Study to Evaluate the Safety and Efficacy of ALXN1720 in Adults with Generalized Myasthenia Gravis No dispute reported 06/30/2026 1185549031
Principal investigator 1 ARGENX US, INC. $2,856.85 07/22/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237151004
Principal investigator 1 ARGENX US, INC. $4,044.00 07/22/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237151050
Principal investigator 1 ARGENX US, INC. $975.00 07/17/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237151000
Principal investigator 1 ARGENX US, INC. $2,425.90 07/17/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
A Phase 3, Single-Arm, Multicenter, Open-label Extension of Study ARGX-113-2007 to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237151041
Principal investigator 1 ARGENX US, INC. $8,128.55 07/17/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237151058
Principal investigator 1 PFIZER INC. $3,990.00 07/11/2025 Non-covered Recipient Entity
Houston Neurocare PA
A PHASE 3 MULTICENTER DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06823859 IN PARTICIPANTS WITH ACTIVE IDIOPATHIC INFLAMMATORY MYOPATHIES INCLUDING PARTICIPANTS WITH ACTIVE DERMATOMYOSITIS OR POLYMYOSITIS No dispute reported 06/30/2026 1228785861
Principal investigator 1 ARGENX US, INC. $1,745.90 07/10/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
A Phase 3, Single-Arm, Multicenter, Open-label Extension of Study ARGX-113-2007 to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237151062
Principal investigator 1 ARGENX US, INC. $1,475.00 07/04/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
A Phase 3, Single-Arm, Multicenter, Open-label Extension of Study ARGX-113-2007 to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237150992
Principal investigator 1 ARGENX US, INC. $8,272.20 07/04/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237151069
Principal investigator 1 ARGENX US, INC. $5,701.50 07/04/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
A Phase 3, Single-Arm, Multicenter, Open-label Extension of Study ARGX-113-2007 to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237151081
Principal investigator 1 ARGENX US, INC. $70.00 07/01/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237151136
Principal investigator 1 PTC Therapeutics, Inc. $10,275.62 06/30/2025 Non-covered Recipient Entity
NERVE AND MUSCLE CENTER OF TEXAS
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL STUDY TO ASSESS THE EFFICACY, SAFETY, TOLERABILITY, PK, AND BIOMARKER EFFECTS OFPTC857IN ADULT SUBJECTS WITHAMYOTROPHIC LATERAL SCLEROSIS(CARDINALS) No dispute reported 06/30/2026 1249093493
Principal investigator 1 PFIZER INC. $6,709.80 06/26/2025 Non-covered Recipient Entity
Houston Neurocare PA
A PHASE 3 MULTICENTER DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06823859 IN PARTICIPANTS WITH ACTIVE IDIOPATHIC INFLAMMATORY MYOPATHIES INCLUDING PARTICIPANTS WITH ACTIVE DERMATOMYOSITIS OR POLYMYOSITIS No dispute reported 06/30/2026 1228724976
Principal investigator 1 ARGENX US, INC. $1,755.00 06/24/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237150875
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $1,879.20 06/23/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
LX9211 No dispute reported 06/30/2026 1248066699
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 06/23/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184210098
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 06/23/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184210100
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 06/23/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184210102
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 06/23/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184210104
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 06/23/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184210106
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 06/23/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184210110
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 06/23/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184210112
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 06/23/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184210114
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 06/23/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184210116
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 06/23/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184210118
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 06/23/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184210120
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 06/23/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184210122
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 06/23/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184210124
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $201.15 06/23/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184210136
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $202.50 06/23/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184210138
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $202.50 06/23/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184210140
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $202.50 06/23/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184210142
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $330.75 06/23/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184210180
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $67.50 06/23/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184210406
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $67.50 06/23/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184210408
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $67.50 06/23/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184210410
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $67.50 06/23/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184210412
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $67.50 06/23/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184210414
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $67.50 06/23/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184210416
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $67.50 06/23/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184210418
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $67.50 06/23/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184210420
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $67.50 06/23/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184210422
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $67.50 06/23/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184210424
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $67.50 06/23/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184210426
Principal investigator 1 ARGENX US, INC. $1,745.90 06/19/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
A Phase 3, Single-Arm, Multicenter, Open-label Extension of Study ARGX-113-2007 to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237150835
Principal investigator 1 ARGENX US, INC. $2,600.00 06/19/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237150879
Principal investigator 1 ARGENX US, INC. $5,559.00 06/19/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237150882
Principal investigator 1 ARGENX US, INC. $5,625.30 06/12/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237150847
Principal investigator 1 GlaxoSmithKline, LLC. $1,954.80 06/11/2025 Non-covered Recipient Entity
NERVE AND MUSCLE CENTER OF TEXAS
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192125874
Principal investigator 1 GlaxoSmithKline, LLC. $1,954.80 06/11/2025 Non-covered Recipient Entity
NERVE AND MUSCLE CENTER OF TEXAS
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192143657
Principal investigator 1 ARGENX US, INC. $2,672.00 06/05/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237150829
Principal investigator 1 ARGENX US, INC. $2,569.55 06/05/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237150851
Principal investigator 1 ARGENX US, INC. $70.00 06/01/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237151122
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,088.66 05/29/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184200201
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,206.33 05/29/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184200203
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,002.60 05/29/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184200205
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,445.63 05/29/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184200207
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,644.05 05/29/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184200209
Principal investigator 1 ARGENX US, INC. $13,333.95 05/28/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237150825
Principal investigator 1 ARGENX US, INC. $2,895.10 05/28/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
A Phase 3, Single-Arm, Multicenter, Open-label Extension of Study ARGX-113-2007 to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237150832
Principal investigator 1 ARGENX US, INC. $3,777.00 05/28/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237150856
Principal investigator 1 GlaxoSmithKline, LLC. $50.00 05/28/2025 Non-covered Recipient Entity
NERVE AND MUSCLE CENTER OF TEXAS
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192124696
Principal investigator 1 GlaxoSmithKline, LLC. $50.00 05/28/2025 Non-covered Recipient Entity
NERVE AND MUSCLE CENTER OF TEXAS
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192125856
Principal investigator 1 GlaxoSmithKline, LLC. $50.00 05/28/2025 Non-covered Recipient Entity
NERVE AND MUSCLE CENTER OF TEXAS
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192130854
Principal investigator 1 GlaxoSmithKline, LLC. $50.00 05/28/2025 Non-covered Recipient Entity
NERVE AND MUSCLE CENTER OF TEXAS
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192130879
Principal investigator 1 GlaxoSmithKline, LLC. $50.00 05/28/2025 Non-covered Recipient Entity
NERVE AND MUSCLE CENTER OF TEXAS
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192130890
Principal investigator 1 GlaxoSmithKline, LLC. $50.00 05/28/2025 Non-covered Recipient Entity
NERVE AND MUSCLE CENTER OF TEXAS
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192133038
Principal investigator 1 GlaxoSmithKline, LLC. $50.00 05/28/2025 Non-covered Recipient Entity
NERVE AND MUSCLE CENTER OF TEXAS
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192133138
Principal investigator 1 GlaxoSmithKline, LLC. $50.00 05/28/2025 Non-covered Recipient Entity
NERVE AND MUSCLE CENTER OF TEXAS
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192133152
Principal investigator 1 GlaxoSmithKline, LLC. $50.00 05/28/2025 Non-covered Recipient Entity
NERVE AND MUSCLE CENTER OF TEXAS
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192133170
Principal investigator 1 GlaxoSmithKline, LLC. $50.00 05/28/2025 Non-covered Recipient Entity
NERVE AND MUSCLE CENTER OF TEXAS
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192133182
Principal investigator 1 GlaxoSmithKline, LLC. $50.00 05/28/2025 Non-covered Recipient Entity
NERVE AND MUSCLE CENTER OF TEXAS
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192143669
Principal investigator 1 GlaxoSmithKline, LLC. $50.00 05/28/2025 Non-covered Recipient Entity
NERVE AND MUSCLE CENTER OF TEXAS
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192182011
Principal investigator 1 GlaxoSmithKline, LLC. $50.00 05/28/2025 Non-covered Recipient Entity
NERVE AND MUSCLE CENTER OF TEXAS
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192182025
Principal investigator 1 GlaxoSmithKline, LLC. $50.00 05/28/2025 Non-covered Recipient Entity
NERVE AND MUSCLE CENTER OF TEXAS
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192182029
Principal investigator 1 GlaxoSmithKline, LLC. $50.00 05/28/2025 Non-covered Recipient Entity
NERVE AND MUSCLE CENTER OF TEXAS
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192182033
Principal investigator 1 GlaxoSmithKline, LLC. $50.00 05/28/2025 Non-covered Recipient Entity
NERVE AND MUSCLE CENTER OF TEXAS
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192183531
Principal investigator 1 ARGENX US, INC. $2,340.00 05/22/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
A Phase 3, Single-Arm, Multicenter, Open-label Extension of Study ARGX-113-2007 to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237150821
Principal investigator 1 GlaxoSmithKline, LLC. $50.00 05/20/2025 Non-covered Recipient Entity
NERVE AND MUSCLE CENTER OF TEXAS
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192130885
Principal investigator 1 GlaxoSmithKline, LLC. $67.50 05/20/2025 Non-covered Recipient Entity
NERVE AND MUSCLE CENTER OF TEXAS
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192144235
Principal investigator 1 GlaxoSmithKline, LLC. $50.00 05/20/2025 Non-covered Recipient Entity
NERVE AND MUSCLE CENTER OF TEXAS
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192182021
Principal investigator 1 ARGENX US, INC. $10,963.30 05/15/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237150893
Principal investigator 1 PFIZER INC. $3,490.20 05/14/2025 Non-covered Recipient Entity
Houston Neurocare PA
A PHASE 3 MULTICENTER DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06823859 IN PARTICIPANTS WITH ACTIVE IDIOPATHIC INFLAMMATORY MYOPATHIES INCLUDING PARTICIPANTS WITH ACTIVE DERMATOMYOSITIS OR POLYMYOSITIS No dispute reported 06/30/2026 1228772161
Principal investigator 1 ARGENX US, INC. $2,412.00 05/02/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237150867
Principal investigator 1 ARGENX US, INC. $104.00 05/01/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237151108
Principal investigator 1 ARGENX US, INC. $70.00 05/01/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237151117
Principal investigator 1 PTC Therapeutics, Inc. $242.90 04/30/2025 Non-covered Recipient Entity
NERVE AND MUSCLE CENTER OF TEXAS
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL STUDY TO ASSESS THE EFFICACY, SAFETY, TOLERABILITY, PK, AND BIOMARKER EFFECTS OFPTC857IN ADULT SUBJECTS WITHAMYOTROPHIC LATERAL SCLEROSIS(CARDINALS) No dispute reported 06/30/2026 1249093381
Principal investigator 1 ARGENX US, INC. $8,283.25 04/28/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237150862
Principal investigator 1 GlaxoSmithKline, LLC. $243.00 04/28/2025 Non-covered Recipient Entity
NERVE AND MUSCLE CENTER OF TEXAS
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192125909
Principal investigator 1 GlaxoSmithKline, LLC. $128.25 04/28/2025 Non-covered Recipient Entity
NERVE AND MUSCLE CENTER OF TEXAS
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192130861
Principal investigator 1 GlaxoSmithKline, LLC. $50.00 04/28/2025 Non-covered Recipient Entity
NERVE AND MUSCLE CENTER OF TEXAS
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192143650
Principal investigator 1 GlaxoSmithKline, LLC. $256.50 04/28/2025 Non-covered Recipient Entity
NERVE AND MUSCLE CENTER OF TEXAS
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192144244
Principal investigator 1 GlaxoSmithKline, LLC. $121.50 04/28/2025 Non-covered Recipient Entity
NERVE AND MUSCLE CENTER OF TEXAS
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192144249
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,140.83 04/25/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184189901
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,656.68 04/25/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184189903
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,445.63 04/25/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184189905
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,206.33 04/25/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184189907
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,805.90 04/25/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184189909
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,120.26 04/25/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184189911
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,088.66 04/25/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184189913
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,002.60 04/25/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184189915
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,002.60 04/25/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184189917
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,552.25 04/25/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184189919
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,088.66 04/25/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184189921
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,552.25 04/25/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184189923
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,110.65 04/25/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184189925
Principal investigator 1 PFIZER INC. $8,811.60 04/24/2025 Non-covered Recipient Entity
Houston Neurocare PA
A PHASE 3 MULTICENTER DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06823859 IN PARTICIPANTS WITH ACTIVE IDIOPATHIC INFLAMMATORY MYOPATHIES INCLUDING PARTICIPANTS WITH ACTIVE DERMATOMYOSITIS OR POLYMYOSITIS No dispute reported 06/30/2026 1228778705
Principal investigator 1 ARGENX US, INC. $27,341.95 04/23/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237150840
Principal investigator 1 ARGENX US, INC. $1,560.00 04/23/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237150871
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $67.50 04/18/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184184810
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 04/18/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184184812
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 04/18/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184184814
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 04/18/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184184816
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 04/18/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184184818
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 04/18/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184184820
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 04/18/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184184822
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 04/18/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184184824
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 04/18/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184184826
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 04/18/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184184828
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 04/18/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184184830
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 04/18/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184184832
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $67.50 04/18/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184184834
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $405.00 04/18/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184184836
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 04/18/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184184838
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $67.50 04/18/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184184840
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $202.50 04/18/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184184842
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 04/18/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184184844
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 04/18/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184184846
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 04/18/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184184848
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 04/18/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184184850
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $67.50 04/18/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184184852
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 04/18/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184184854
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 04/18/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184184856
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 04/18/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184184858
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $67.50 04/18/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184184860
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 04/18/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184184862
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $67.50 04/18/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184184864
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 04/18/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184184866
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 04/18/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184184868
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $202.50 04/18/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184184870
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 04/18/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184184872
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $67.50 04/18/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184184874
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $67.50 04/18/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184184876
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 04/18/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184184878
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 04/18/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184184880
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 04/18/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184184882
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $67.50 04/18/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184184884
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 04/18/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184184886
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $67.50 04/18/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184184888
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 04/18/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184184890
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $67.50 04/18/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184184893
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 04/18/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184184895
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $67.50 04/18/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184184897
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $330.75 04/18/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184184899
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $201.15 04/18/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184184901
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 04/18/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184184903
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $67.50 04/18/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184184905
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $67.50 04/18/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184184907
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 04/18/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184184909
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 04/18/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184184911
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $330.75 04/18/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184184913
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 04/18/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184184915
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $201.15 04/18/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184184917
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 04/18/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184184919
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 04/18/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184184921
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 04/18/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184184923
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $202.50 04/18/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184184925
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 04/18/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184184927
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 04/18/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184184929
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $67.50 04/18/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184184931
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $330.75 04/18/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184184933
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $202.50 04/18/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184184935
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $201.15 04/18/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184184937
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 04/18/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184184939
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $67.50 04/18/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184184941
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $67.50 04/18/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184184943
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 04/18/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184184945
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $67.50 04/18/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184184947
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $67.50 04/18/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184184949
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 04/18/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184184951
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $202.50 04/18/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184184953
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 04/18/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184184955
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $67.50 04/18/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184184957
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 04/18/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184184959
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $500.00 04/18/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184184961
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $67.50 04/18/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184184963
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $201.15 04/18/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184184965
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $330.75 04/18/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184184967
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 04/18/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184184969
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 04/18/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184184971
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 04/18/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184184973
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $67.50 04/18/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184184975
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 04/18/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184184977
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $201.15 04/18/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184184979
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 04/18/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184184981
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $330.75 04/18/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184184983
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 04/18/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184184985
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $67.50 04/18/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184184987
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $202.50 04/18/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184184989
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $80.00 04/18/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184184991
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $405.00 04/18/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184184993
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $337.50 04/18/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184184995
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 04/18/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184184997
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 04/18/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184184999
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $67.50 04/18/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184185001
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 04/18/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184185003
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 04/18/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184185005
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 04/18/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184185007
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 04/18/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184185009
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $67.50 04/18/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184185011
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 04/18/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184185013
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 04/18/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184185015
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 04/18/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184185017
Principal investigator 1 ARGENX US, INC. $1,950.00 04/15/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237150818
Principal investigator 1 Amgen Inc. $23,375.00 04/14/2025 Non-covered Recipient Entity
NERVE AND MUSCLE CENTER OF TEXAS
P3 Inebilizumab in Adults w/MG (MINT) No dispute reported 06/30/2026 1246645020
Principal investigator 1 ARGENX US, INC. $5,679.70 04/08/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237150843
Principal investigator 1 ARGENX US, INC. $390.00 04/08/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
A Phase 3, Single-Arm, Multicenter, Open-label Extension of Study ARGX-113-2007 to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237150887
Principal investigator 1 ARGENX US, INC. $2,839.85 04/01/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237150814
Principal investigator 1 ARGENX US, INC. $70.00 04/01/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237151112
Principal investigator 1 ARGENX US, INC. $2,967.35 03/25/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237150787
Principal investigator 1 ARGENX US, INC. $2,895.10 03/19/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
A Phase 3, Single-Arm, Multicenter, Open-label Extension of Study ARGX-113-2007 to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237150796
Principal investigator 1 ARGENX US, INC. $6,166.75 03/19/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237150809
Principal investigator 1 PTC Therapeutics, Inc. $8,692.50 03/17/2025 Non-covered Recipient Entity
NERVE AND MUSCLE CENTER OF TEXAS
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL STUDY TO ASSESS THE EFFICACY, SAFETY, TOLERABILITY, PK, AND BIOMARKER EFFECTS OFPTC857IN ADULT SUBJECTS WITHAMYOTROPHIC LATERAL SCLEROSIS(CARDINALS) No dispute reported 06/30/2026 1249093293
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $20,289.00 03/14/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
LX9211.1-204-DPN No dispute reported 06/30/2026 1248067257
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $6,003.00 03/14/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
LX9211.1-204-DPN No dispute reported 06/30/2026 1248067259
Principal investigator 1 ARGENX US, INC. $8,725.25 03/11/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237150761
Principal investigator 1 ARGENX US, INC. $2,535.00 03/11/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237150771
Principal investigator 1 ARGENX US, INC. $2,895.10 03/11/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
A Phase 3, Single-Arm, Multicenter, Open-label Extension of Study ARGX-113-2007 to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237150805
Principal investigator 1 ARGENX US, INC. $6,904.00 03/06/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
A Phase 3, Single-Arm, Multicenter, Open-label Extension of Study ARGX-113-2007 to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237150800
Principal investigator 1 ARGENX US, INC. $2,569.55 03/04/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237150781
Principal investigator 1 ARGENX US, INC. $8,847.00 03/04/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237150792
Principal investigator 1 ARGENX US, INC. $70.00 03/01/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237151105
Principal investigator 1 GlaxoSmithKline, LLC. $121.50 02/27/2025 Non-covered Recipient Entity
NERVE AND MUSCLE CENTER OF TEXAS
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192124691
Principal investigator 1 GlaxoSmithKline, LLC. $486.00 02/27/2025 Non-covered Recipient Entity
NERVE AND MUSCLE CENTER OF TEXAS
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192125863
Principal investigator 1 GlaxoSmithKline, LLC. $243.00 02/27/2025 Non-covered Recipient Entity
NERVE AND MUSCLE CENTER OF TEXAS
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192125880
Principal investigator 1 GlaxoSmithKline, LLC. $121.50 02/27/2025 Non-covered Recipient Entity
NERVE AND MUSCLE CENTER OF TEXAS
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192133032
Principal investigator 1 GlaxoSmithKline, LLC. $243.00 02/27/2025 Non-covered Recipient Entity
NERVE AND MUSCLE CENTER OF TEXAS
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192133058
Principal investigator 1 GlaxoSmithKline, LLC. $243.00 02/27/2025 Non-covered Recipient Entity
NERVE AND MUSCLE CENTER OF TEXAS
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192133080
Principal investigator 1 GlaxoSmithKline, LLC. $243.00 02/27/2025 Non-covered Recipient Entity
NERVE AND MUSCLE CENTER OF TEXAS
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192143653
Principal investigator 1 GlaxoSmithKline, LLC. $607.50 02/27/2025 Non-covered Recipient Entity
NERVE AND MUSCLE CENTER OF TEXAS
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192143666
Principal investigator 1 GlaxoSmithKline, LLC. $243.00 02/27/2025 Non-covered Recipient Entity
NERVE AND MUSCLE CENTER OF TEXAS
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192182008
Principal investigator 1 PFIZER INC. $2,979.25 02/26/2025 Non-covered Recipient Entity
Houston Neurocare PA
A PHASE 3 MULTICENTER DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06823859 IN PARTICIPANTS WITH ACTIVE IDIOPATHIC INFLAMMATORY MYOPATHIES INCLUDING PARTICIPANTS WITH ACTIVE DERMATOMYOSITIS OR POLYMYOSITIS No dispute reported 06/30/2026 1228720145
Principal investigator 1 ARGENX US, INC. $5,765.60 02/25/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237150764
Principal investigator 1 ARGENX US, INC. $2,856.85 02/11/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237150758
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,644.05 02/10/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184152880
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,758.80 02/10/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184152882
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,987.78 02/10/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184152884
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,805.85 02/10/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184152886
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,618.19 02/10/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184152888
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,552.25 02/10/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184152890
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,805.85 02/10/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184152892
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,552.25 02/10/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184152894
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,552.25 02/10/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184152896
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,140.83 02/10/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184152898
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,656.68 02/10/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184152900
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,758.80 02/10/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184152902
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,987.78 02/10/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184152904
Principal investigator 1 GlaxoSmithKline, LLC. $1,759.32 02/06/2025 Non-covered Recipient Entity
NERVE AND MUSCLE CENTER OF TEXAS
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192144258
Principal investigator 1 ARGENX US, INC. $8,570.55 02/05/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237150751
Principal investigator 1 PFIZER INC. $10,052.00 02/05/2025 Non-covered Recipient Entity
Houston Neurocare PA
A PHASE 3 MULTICENTER OPENLABEL EXTENSION STUDY TO INVESTIGATE THE LONGTERM SAFETY TOLERABILITY AND EFFICACY OF DAZUKIBART IN PARTICIPANTS WITH IDIOPATHIC INFLAMMATORY MYOPATHIES INCLUDING PARTICIPANTS WITH DERMATOMYOSITIS OR POLYMYOSITIS No dispute reported 06/30/2026 1228753902
Principal investigator 1 ARGENX US, INC. $104.00 02/01/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237151089
Principal investigator 1 ARGENX US, INC. $70.00 02/01/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237151101
Principal investigator 1 Novartis Pharmaceuticals Corporation $370,401.94 01/31/2025 Non-covered Recipient Entity
NERVE AND MUSCLE CENTER OF TEXAS
A phase 2, randomized, double-blind, placebo-controlled parallel group study of VHB937 in Amyotrophic Lateral Sclerosis (ALS) over 40 weeks followed by an Open-label Extension (ASTRALS) No dispute reported 06/30/2026 1190302537
Principal investigator 1 PTC Therapeutics, Inc. $5,000.00 01/30/2025 Non-covered Recipient Entity
NERVE AND MUSCLE CENTER OF TEXAS
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL STUDY TO ASSESS THE EFFICACY, SAFETY, TOLERABILITY, PK, AND BIOMARKER EFFECTS OFPTC857IN ADULT SUBJECTS WITHAMYOTROPHIC LATERAL SCLEROSIS(CARDINALS) No dispute reported 06/30/2026 1249093163
Principal investigator 1 PTC Therapeutics, Inc. $2,173.50 01/30/2025 Non-covered Recipient Entity
NERVE AND MUSCLE CENTER OF TEXAS
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL STUDY TO ASSESS THE EFFICACY, SAFETY, TOLERABILITY, PK, AND BIOMARKER EFFECTS OFPTC857IN ADULT SUBJECTS WITHAMYOTROPHIC LATERAL SCLEROSIS(CARDINALS) No dispute reported 06/30/2026 1249093165
Principal investigator 1 ARGENX US, INC. $2,856.85 01/29/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237150777
Principal investigator 1 GlaxoSmithKline, LLC. $249.75 01/28/2025 Non-covered Recipient Entity
NERVE AND MUSCLE CENTER OF TEXAS
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192130867
Principal investigator 1 GlaxoSmithKline, LLC. $249.75 01/28/2025 Non-covered Recipient Entity
NERVE AND MUSCLE CENTER OF TEXAS
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192130896
Principal investigator 1 GlaxoSmithKline, LLC. $411.75 01/28/2025 Non-covered Recipient Entity
NERVE AND MUSCLE CENTER OF TEXAS
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192133025
Principal investigator 1 GlaxoSmithKline, LLC. $67.50 01/28/2025 Non-covered Recipient Entity
NERVE AND MUSCLE CENTER OF TEXAS
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192133066
Principal investigator 1 GlaxoSmithKline, LLC. $729.00 01/28/2025 Non-covered Recipient Entity
NERVE AND MUSCLE CENTER OF TEXAS
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192133073
Principal investigator 1 GlaxoSmithKline, LLC. $729.00 01/28/2025 Non-covered Recipient Entity
NERVE AND MUSCLE CENTER OF TEXAS
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192133130
Principal investigator 1 GlaxoSmithKline, LLC. $67.50 01/28/2025 Non-covered Recipient Entity
NERVE AND MUSCLE CENTER OF TEXAS
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192133146
Principal investigator 1 GlaxoSmithKline, LLC. $67.50 01/28/2025 Non-covered Recipient Entity
NERVE AND MUSCLE CENTER OF TEXAS
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192133159
Principal investigator 1 GlaxoSmithKline, LLC. $67.50 01/28/2025 Non-covered Recipient Entity
NERVE AND MUSCLE CENTER OF TEXAS
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192133164
Principal investigator 1 GlaxoSmithKline, LLC. $67.50 01/28/2025 Non-covered Recipient Entity
NERVE AND MUSCLE CENTER OF TEXAS
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192133176
Principal investigator 1 GlaxoSmithKline, LLC. $67.50 01/28/2025 Non-covered Recipient Entity
NERVE AND MUSCLE CENTER OF TEXAS
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192143661
Principal investigator 1 GlaxoSmithKline, LLC. $67.50 01/28/2025 Non-covered Recipient Entity
NERVE AND MUSCLE CENTER OF TEXAS
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192143674
Principal investigator 1 GlaxoSmithKline, LLC. $100.00 01/28/2025 Non-covered Recipient Entity
NERVE AND MUSCLE CENTER OF TEXAS
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192144254
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $9,160.20 01/22/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
LX9211.1-204-DPN No dispute reported 06/30/2026 1248067813
Principal investigator 1 ARGENX US, INC. $14,300.40 01/17/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237150745
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $5,327.00 01/17/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
LX9211.1-204-DPN No dispute reported 06/30/2026 1248067811
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $2,644.20 01/14/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
LX9211.1-204-DPN No dispute reported 06/30/2026 1248067809
Principal investigator 1 ARGENX US, INC. $8,685.30 01/07/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
A Phase 3, Single-Arm, Multicenter, Open-label Extension of Study ARGX-113-2007 to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237150754
Principal investigator 1 ARGENX US, INC. $11,339.90 01/07/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237150768
Principal investigator 1 GlaxoSmithKline, LLC. $121.50 01/07/2025 Non-covered Recipient Entity
NERVE AND MUSCLE CENTER OF TEXAS
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192125885
Principal investigator 1 GlaxoSmithKline, LLC. $128.25 01/07/2025 Non-covered Recipient Entity
NERVE AND MUSCLE CENTER OF TEXAS
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192125891
Principal investigator 1 GlaxoSmithKline, LLC. $121.50 01/07/2025 Non-covered Recipient Entity
NERVE AND MUSCLE CENTER OF TEXAS
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192125896
Principal investigator 1 GlaxoSmithKline, LLC. $121.50 01/07/2025 Non-covered Recipient Entity
NERVE AND MUSCLE CENTER OF TEXAS
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192125902
Principal investigator 1 GlaxoSmithKline, LLC. $121.50 01/07/2025 Non-covered Recipient Entity
NERVE AND MUSCLE CENTER OF TEXAS
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192130873
Principal investigator 1 GlaxoSmithKline, LLC. $121.50 01/07/2025 Non-covered Recipient Entity
NERVE AND MUSCLE CENTER OF TEXAS
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192133045
Principal investigator 1 GlaxoSmithKline, LLC. $121.50 01/07/2025 Non-covered Recipient Entity
NERVE AND MUSCLE CENTER OF TEXAS
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192133052
Principal investigator 1 GlaxoSmithKline, LLC. $128.25 01/07/2025 Non-covered Recipient Entity
NERVE AND MUSCLE CENTER OF TEXAS
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192143678
Principal investigator 1 GlaxoSmithKline, LLC. $128.25 01/07/2025 Non-covered Recipient Entity
NERVE AND MUSCLE CENTER OF TEXAS
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192144240
Principal investigator 1 GlaxoSmithKline, LLC. $128.25 01/07/2025 Non-covered Recipient Entity
NERVE AND MUSCLE CENTER OF TEXAS
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192144265
Principal investigator 1 GlaxoSmithKline, LLC. $128.25 01/07/2025 Non-covered Recipient Entity
NERVE AND MUSCLE CENTER OF TEXAS
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192182016
Principal investigator 1 GlaxoSmithKline, LLC. $128.25 01/07/2025 Non-covered Recipient Entity
NERVE AND MUSCLE CENTER OF TEXAS
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192183528
Principal investigator 1 ARGENX US, INC. $70.00 01/01/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237151093
Principal investigator 1 ARGENX US, INC. $104.00 01/01/2025 Non-covered Recipient Entity
HOUSTON NEUROCARE PA
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237151097